Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2021; 56(04): 478-484
DOI: 10.1055/s-0040-1721839
Artigo Original
Mão

Epidemiology of Dupuytren disease and Patients Undergoing Selective Fasciectomy[*]

Article in several languages: português | English
Fernando Henrique Uchôa de Alencar 
1   Centro de Cirurgia da Mão, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil
,
Jamila Alessandra Perini 
2   Divisão de Pesquisa, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil
3   Unidade de Farmácia, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, RJ, Brasil
,
Anderson Vieira Monteiro 
1   Centro de Cirurgia da Mão, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil
,
Maria Eugenia Leite Duarte 
2   Divisão de Pesquisa, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil
,
Geraldo da Rocha Motta 
2   Divisão de Pesquisa, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil
,
João Antônio Matheus Guimarães 
2   Divisão de Pesquisa, Instituto Nacional de Traumatologia e Ortopedia, Rio de Janeiro, RJ, Brasil
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective To describe the epidemiological and clinical profile of patients with Dupuytren disease treated by selective fasciectomy and the factors associated with the severity of the disease.

Methods Retrospective descriptive observational study involving 247 patients with Dupuytren disease, from 2013 to 2019. Multivariate logistic regression was performed for data analysis.

Results Most patients were male (83.8%), self-declared white (65.2%), alcoholics (59.6%) and 49% were smokers, with a mean age of 66 ± 9 years old, with 77.2% presenting symptoms of the disease after the age of 51 years old. Approximately 51.9, 29.6 and 17.3%, respectively, had arterial hypertension, diabetes mellitus and dyslipidemia comorbidities. Bilateral involvement of the hands was observed in 73.3% of the patients. The rate of intra- and post-selective fasciectomy complications was of 0.6 and 24.3%, respectively, with 5.2% of the patients needing reintervention after 1 year of follow-up. After multivariate analysis, males were associated with bilateral involvement of the hands (odds ratio [OR] = 2.10; 95% confidence interval [CI]: 1.03–4.31) and with a greater number of affected rays (OR = 3.41; 95% CI: 1.66–7.03). Dyslipidemia was associated with reintervention (OR = 5.7; 95% CI = 1.03–31.4) and bilaterality with a higher number of complications (35.7 versus 19.7%).

Conclusion A low rate of reintervention and operative complications was observed in patients with Dupuytren disease treated by selective fasciectomy. Male gender was associated with severe disease (bilaterality and more than two affected rays), and dyslipidemia with reintervention.

Keywords

dupuytren disease - fasciectomy - risk factors - operative complications - reintervention

Financial Support

There was no financial support from public, commercial, or non-profit sources.


* Study developed at Instituto Nacional de Traumatologia e Ortopedia (INTO), Rio de Janeiro, RJ, Brazil.




Publication History

Received: 22 April 2020

Accepted: 17 September 2020

Article published online:
22 March 2021

© 2021. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referências

  • 1 Liu H, Yin W, Liu B, Liu Y, Guo B, Wei Z. Screening of candidate genes in fibroblasts derived from patients with Dupuytren's contracture using bioinformatics analysis. Rheumatol Int 2015; 35 (08) 1343-1350
    CrossrefPubMedGoogle Scholar
  • 2 Staats KA, Wu T, Gan BS, O'Gorman DB, Ophoff RA. Dupuytren's disease susceptibility gene, EPDR1, is involved in myofibroblast contractility. J Dermatol Sci 2016; 83 (02) 131-137
    CrossrefPubMedGoogle Scholar
  • 3 Becker K, Siegert S, Toliat MR. et al; German Dupuytren Study Group. Meta-analysis of genome-wide association studies and network analysis-based integration with gene expression data identify new suggestive loci and unravel a Wnt-centric network associated with Dupuytren's disease. PLoS One 2016; 11 (07) e0158101
    CrossrefPubMedGoogle Scholar
  • 4 Ji X, Tian F, Tian L. Identification and function analysis of contrary genes in Dupuytren's contracture. Mol Med Rep 2015; 12 (01) 482-488
    CrossrefPubMedGoogle Scholar
  • 5 Mansur HG, Oliveira ER, Gonçalves CB. Epidemiological analysis of patients with Dupuytren's disease. Rev Bras Ortop 2017; 53 (01) 10-14
    Google Scholar
  • 6 Ribak S, Borkowski Jr R, do Amaral RP, Massato A, Ávila I, de Andrade D. Dupuytren contracture: comparative study between partial fasciectomy and percutaneous fasciectomy. [Contratura de Dupuytren: estudo comparativo entre fasciectomia parcial e fasciotomia percutânea]. Rev Bras Ortop 2014; 48 (06) 545-553
    CrossrefPubMedGoogle Scholar
  • 7 Dias JJ, Braybrooke J. Dupuytren's contracture: an audit of the outcomes of surgery. J Hand Surg Br 2006; 31 (05) 514-521
    CrossrefPubMedGoogle Scholar
  • 8 Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol 2010; 6 (12) 715-726
    CrossrefPubMedGoogle Scholar
  • 9 Smith AC. Diagnosis and indications for surgical treatment. Hand Clin 1991; 7 (04) 635-642
    CrossrefPubMedGoogle Scholar
  • 10 Desai SS, Hentz VR. The treatment of Dupuytren disease. J Hand Surg Am 2011; 36 (05) 936-942
    CrossrefPubMedGoogle Scholar
  • 11 Werker PM, Pess GM, van Rijssen AL, Denkler K. Correction of contracture and recurrence rates of Dupuytren contracture following invasive treatment: the importance of clear definitions. J Hand Surg Am 2012; 37 (10) 2095-2105.e7
    CrossrefPubMedGoogle Scholar
  • 12 Poelstra R, van Kooij YE, van der Oest MJW, Slijper HP, Hovius SER, Selles RW. Hand-Wrist Study Group. Patient's satisfaction beyond hand function in Dupuytren's disease: analysis of 1106 patients. J Hand Surg Eur Vol 2020; 45 (03) 280-285
    CrossrefPubMedGoogle Scholar
  • 13 Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y) 2009; 4 (03) 256-269
    CrossrefPubMedGoogle Scholar
  • 14 Barros F, Barros A, Almeida SF. Enfermidade de Dupuytren: avaliação de 100 casos. Rev Bras Ortop 1997; 32 (03) 177-183
    Google Scholar
  • 15 Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am 2006; 31 (10) 1626-1634
    CrossrefPubMedGoogle Scholar
  • 16 Dolmans GH, de Bock GH, Werker PM. Dupuytren diathesis and genetic risk. J Hand Surg Am 2012; 37 (10) 2106-2111
    CrossrefPubMedGoogle Scholar
  • 17 Carloni R, Gandolfi S, Elbaz B, Bonmarchand A, Beccari R, Auquit-Auckbur I. Dorsal Dupuytren's disease: a systematic review of published cases and treatment options. J Hand Surg Eur Vol 2019; 44 (09) 963-971
    CrossrefPubMedGoogle Scholar
  • 18 Hahn P. Epidemiologie des Morbus Dupuytren. Orthopade 2017; 46 (04) 298-302
    CrossrefPubMedGoogle Scholar
  • 19 Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997; 79 (02) 206-210
    CrossrefPubMedGoogle Scholar
  • 20 Broekstra DC, Groen H, Molenkamp S, Werker PMN, van den Heuvel ER. A Systematic Review and Meta-Analysis on the Strength and Consistency of the Associations between Dupuytren Disease and Diabetes Mellitus, Liver Disease, and Epilepsy. Plast Reconstr Surg 2018; 141 (03) 367e-379e
    CrossrefPubMedGoogle Scholar
  • 21 Yuen A, Laschinger C, Talior I. et al. Methylglyoxal-modified collagen promotes myofibroblast differentiation. Matrix Biol 2010; 29 (06) 537-548
    CrossrefPubMedGoogle Scholar
  • 22 Leafblad ND, Wagner E, Wanderman NR. et al. Outcomes and Direct Costs of Needle Aponeurotomy, Collagenase Injection, and Fasciectomy in the Treatment of Dupuytren Contracture. J Hand Surg Am 2019; 44 (11) 919-927
    CrossrefPubMedGoogle Scholar
  • 23 Hindocha S. Risk Factors, Disease Associations, and Dupuytren Diathesis. Hand Clin 2018; 34 (03) 307-314
    CrossrefPubMedGoogle Scholar
  • 24 Denkler K. Surgical complications associated with fasciectomy for dupuytren's disease: a 20-year review of the English literature. Eplasty 2010; 10: e15
    PubMedGoogle Scholar
  • 25 Dias JJ, Aziz S. Fasciectomy for Dupuytren Contracture. Hand Clin 2018; 34 (03) 351-366
    CrossrefPubMedGoogle Scholar